The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.

The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome. - The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007057

Enrollment

Registered

2012-01-12

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea Syndrome

Interventions

We randomly assign hypertensive patients with sleep apnea to treatment with irbesartan, 100mg daily, with morning administration or with evening administration for 24 weeks. After 12 weeks, each admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with sleep apnea syndrome treated with oral appliance or nasal CPAP. 2. Hypertensive patient diagnosed by JSH 2009. 3. Patient should be treated with good compliance by oral appliance or nasal CPAP (usage: >=4 hours daily and >=5 days)

Exclusion criteria

Exclusion criteria: 1. Patient from whom written informed consent is not obtained. 2. Not hypertensive patient. 3. Patient who has the hypersensitivity to irbesartan. 4. Pregnant woman and possible possible pregnant woman.

Design outcomes

Primary

Measure	Time frame
Blood pressure	—

Secondary

Measure	Time frame
Heart rate, Urine albumin, CRP, Body weight/Waist circumference, Adiponectin	—

Countries

Japan

Contacts

Public ContactMeiyo Tamaoka

Tokyo Medical & Dental University University Hospital of Medicine

meiyou2.pulm@tmd.ac.jp81-3-5803-4967

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026